0001209191-23-007494.txt : 20230207
0001209191-23-007494.hdr.sgml : 20230207
20230207160840
ACCESSION NUMBER: 0001209191-23-007494
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230203
FILED AS OF DATE: 20230207
DATE AS OF CHANGE: 20230207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RENSCHLER MARKUS MD
CENTRAL INDEX KEY: 0001217598
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40499
FILM NUMBER: 23595137
MAIL ADDRESS:
STREET 1: C/O PHARMACYCLICS INC
STREET 2: 995 E ARQUES AVE
CITY: SUNNYVALE
STATE: CA
ZIP: 94085-4521
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662244
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 455429901
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING A, SUITE 510
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 857-285-4140
MAIL ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING A, SUITE 510
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-03
0
0001662244
Cyteir Therapeutics, Inc.
CYT
0001217598
RENSCHLER MARKUS MD
C/O CYTEIR THERAPEUTICS, INC.
128 SPRING ST, BUILDING A, SUITE 510
LEXINGTON
MA
02421
1
1
0
0
President and CEO
Common Stock
2023-01-13
5
A
0
E
5000
1.49
A
983736
D
Stock Option (Right to Buy)
1.69
2023-02-03
4
A
0
302600
0.00
A
2033-02-03
Common Stock
302600
302600
D
The reporting person is voluntarily reporting the acquisition of the Company's common stock pursuant to the Cyteir Therapeutics, Inc. Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of July 15, 2022 through January 13, 2023. This transaction is also exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price January 13, 2023, the last trading day of the purchase period.
The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments after the grant date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.
/s/ Adam M. Veness, as attorney-in-fact for Markus Renschler, M.D.
2023-02-07